

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Neurol Neuroimmunol Neuroinflamm 2022;9:e200036. doi:10.1212/NXI.0000000000200036

In the Clinical/Scientific Note “Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod” by Palomares Cabeza et al.,¹ the final name in Appendix 2 should be listed as “C.A.C.M. van Els.” The authors regret the error.

REFERENCE

1. Palomares Cabeza V, Kummer LYL, Wieske L, et al. Longitudinal T-cell responses after a third SARS-CoV-2 vaccination in patients with multiple sclerosis on ocrelizumab or fingolimod. *Neurol Neuroimmunol Neuroinflamm*. 2022;9(4):e1178.

Neurology[®] Neuroimmunology & Neuroinflammation

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Neurol Neuroimmunol Neuroinflamm 2022;9;
DOI 10.1212/NXI.0000000000200036

This information is current as of August 26, 2022

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/9/6/e200036.full.html
References	This article cites 1 articles, 1 of which you can access for free at: http://nn.neurology.org/content/9/6/e200036.full.html##ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2022 American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.

